Mucopolysaccharidoses: Clinical Trials

15 trials for Mucopolysaccharidoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 2 terminated, 1 enrolling by invitation, 1 recruiting. 15 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 415Completed 10, Terminated 2, Enrolling by invitation 1, Recruiting 1, Withdrawn 1

Follow Mucopolysaccharidoses: new trials by email Literature Review of Mucopolysaccharidoses trials Research Report on Mucopolysaccharidoses

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of ELAPRASE in Treatment-naïve Participants With Hunter Syndrome (Mucopolysaccharidosis [MPS] II)
ELAPRASE, Rituximab, Methotrexate - Mucopolysaccharidosis (MPS), Hunter Syndrome
Phase 4WithdrawnTakeda2023-02-282025-12-09
Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
AX 250 - MPS III B
Phase 4Enrolling by invitationAllievex Corporation152022-12-022023-08-09
A Study of Elaprase in Children and Adults With Hunter Syndrome (Mucopolysaccharidosis II) in India
Elaprase - Hunter Syndrome
Phase 4CompletedTakeda52022-04-212025-01-23
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
Laronidase - Mucopolysaccharidosis I
Phase 4CompletedGenzyme, a Sanofi Company122021-10-282025-09-17
Awareness in Old Aged Patients During Laryngoscopy and Intubation Using Isolated Forearm Technique
Sevoflurane, TIVA - Awareness, Anesthesia, Recall Phenomenon
Phase 4CompletedAin Shams University502021-09-052022-01-13
Effects of Bisphosphonates on OI-Related Hearing Loss
Risedronate Oral Tablet - Osteogenesis Imperfecta
Phase 4RecruitingHospital for Special Surgery, New York1002019-11-022026-04-28
Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age
Elaprase for intravenous (IV) infusion - Hunter Syndrome
Phase 4CompletedShire212015-10-282026-04-02
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
Laronidase - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4TerminatedGenzyme, a Sanofi Company22010-10-222024-02-20
Pregabalin and Colonic Function
Pregabalin, Placebo, Bowel preparation - Healthy
Phase 4CompletedMayo Clinic622010-03-012012-03-07
Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial
curcumin, placebo - Irritable Bowel Syndrome
Phase 4CompletedKaiser Permanente172008-11-012015-03-11
Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy
Idursulfase - Hunter Syndrome, Mucopolysaccharidosis II
Phase 4CompletedShire282007-12-312021-06-08
A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI
Naglazyme - Mucopolysaccharidosis VI, Maroteaux-Lamy Syndrome
Phase 4CompletedBioMarin Pharmaceutical42006-05-012011-07-22
Morquio's Syndrome: a Case Study
physiotherapeutic treatment - Morquio's Disease
Phase 4TerminatedClínica de Hidroterapia e Recuperacao Funcional12006-01-012008-10-20
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
Aldurazyme (Recombinant Human Alpha-L-Iduronidase) - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4CompletedGenzyme, a Sanofi Company342004-12-012015-04-03
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
laronidase - Mucopolysaccharidosis I, Hurler's Syndrome
Phase 4CompletedGenzyme, a Sanofi Company252004-07-012014-05-05

Narrower conditions

Mucopolysaccharidosis IV (5)  ·  Mucopolysaccharidosis I (4)  ·  Mucopolysaccharidosis II (4)  ·  Abdominal Pain (1)  ·  Brittle Bone Disorder (1)  ·  Constipation (1)  ·  Diarrhea (1)  ·  Hearing Loss (1)  ·  Intraoperative Awareness (1)  ·  Irritable Bowel Syndrome (1)  ·  Lysosomal Storage Diseases (1)  ·  Mucopolysaccharidosis III (1)  ·  Mucopolysaccharidosis VI (1)  ·  Osteogenesis Imperfecta (1)

Broader conditions

Carbohydrate Metabolism, Inborn Errors (15)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (15)  ·  Connective Tissue Diseases (15)  ·  Genetic Diseases, Inborn (15)  ·  Metabolic Diseases (15)  ·  Metabolism, Inborn Errors (15)  ·  Mucinoses (15)  ·  Nutritional and Metabolic Diseases (15)  ·  Skin and Connective Tissue Diseases (15)  ·  Lysosomal Storage Diseases (14)  ·  Neurologic Manifestations (7)  ·  Nervous System Diseases (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Genetic Diseases, X-Linked (4)

Interventions

Iduronidase (4)  ·  idursulfase (4)  ·  Cathartics (1)  ·  Curcumin (1)  ·  Golytely (1)  ·  Immunoglobulins, Intravenous (1)  ·  Methotrexate (1)  ·  Pregabalin (1)  ·  Risedronic Acid (1)  ·  Rituximab (1)  ·  Sevoflurane (1)  ·  galsulfase (1)

Sponsors

Genzyme, a Sanofi Company (4)  ·  Shire (2)  ·  Takeda (2)  ·  Ain Shams University (1)  ·  Allievex Corporation (1)  ·  BioMarin Pharmaceutical (1)  ·  Clínica de Hidroterapia e Recuperacao Funcional (1)  ·  Hospital for Special Surgery, New York (1)  ·  Kaiser Permanente (1)  ·  Mayo Clinic (1)

Countries

United States (8)  ·  Brazil (2)  ·  Germany (2)  ·  Canada (1)  ·  China (1)  ·  Colombia (1)  ·  Dominican Republic (1)  ·  Egypt (1)  ·  France (1)  ·  India (1)  ·  Italy (1)  ·  Malaysia (1)  ·  Philippines (1)  ·  Poland (1)  ·  Portugal (1)

Top investigators

Cathleen Raggio, MD (1)  ·  Celeste Decker, MD (1)  ·  Michael Camilleri, MD (1)

Results publications

PMID 21596994, PMID 22393902, PMID 24108527, PMID 25864295, PMID 25902842, PMID 33775523, PMID 41163043

NIH funding

1RC1DK086182 (1), 2014 (1), R01DK067071 (1), R01DK079866 (1), UL1RR024150 (1)